Pegaptanib octasodium for the treatment of diabetic macular edema
Pegaptanib octasodium for the treatment of diabetic macular edema
复制标题
哌加他尼八钠治疗糖尿病性黄斑水肿
DOI：
--
复制
发表时间：
2011
影响因子：
3.2
通讯作者：
David G. Miller
中科院分区：
文献类型：
--
作者：
J. Schartman;J. Coney;Joan H. Hornik;David G. Miller
简介：糖尿病性黄斑水肿的治疗已发展为常用的可注射药物，其阻断导致血管渗出的致病途径，其中最重要的是血管内皮生长因子（VEGF）。哌加他尼是一种重要的药物，已在临床上用于治疗糖尿病性黄斑水肿。涵盖的领域：使用术语“糖尿病黄斑水肿”、“糖尿病视网膜病变”、“血管内皮生长因子”和“培加他尼”在Medline上进行文献检索。然后对相关论文和引文进行了审查。专家观点：糖尿病性黄斑水肿是导致工作年龄人群视力下降的最常见原因。因此，重要的是要确定治疗，将允许更迅速和完整的改善视觉功能。哌加他尼在治疗糖尿病性黄斑水肿方面具有许多优势。对于累及中心的水肿，它可能比单独的激光治疗更有效，并且可能比泛VEGF阻断剂具有更好的安全性。
Introduction: The treatment of diabetic macular edema has evolved into the common use of injectable medications that block the pathogenic pathways that lead to vascular exudation, the most important of which is vascular endothelial growth factor (VEGF). Pegaptanib is an important medication that has been used clinically in the treatment of diabetic macular edema. Areas covered: A literature search was done on Medline using the terms ‘diabetic macular edema’, ‘diabetic retinopathy’, ‘vascular endothelial growth factor’ and ‘pegaptanib’. The relevant papers and citations were then reviewed. Expert opinion: Diabetic macular edema is the most common cause of visual loss in working-age people. Thus it is important to identify treatments that will allow a more prompt and complete improvement of visual function. Pegaptanib has many advantages in the treatment of diabetic macular edema. It may be more effective than laser therapy alone for center-involving edema and may have a better safety profile than pan-VEGF blocking agents.
登录
查看更多内容
影响因子：
158.5
作者：
Hurwitz, H;Fehrenbacher, L;Kabbinavar, F
通讯作者：
Kabbinavar, F
DOI：
10.1152/ajpheart.00133.2005
发表时间：
2006-02-01
影响因子：
4.8
作者：
Kamba, T;Tam, BYY;McDonald, DM
通讯作者：
McDonald, DM
影响因子：
13.7
作者：
Diabetic Retinopathy Clinical Research Network
通讯作者：
Diabetic Retinopathy Clinical Research Network
影响因子：
158.5
作者：
Yang, JC;Haworth, L;Rosenberg, SA
通讯作者：
Rosenberg, SA